Published on
November 29, 2018
- 21:01 GMT
Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program
- Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of starting PRN1008 - - Demonstrated sustained clinical efficacy at 12 weeks of therapy, a secondary endpoint - - Initiated global Phase 3 …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
